17:34 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Block coagulation Mouse studies suggest that ANGPT1 could help treat disseminated intravascular coagulation (DIC) associated with sepsis. In lipopolysaccharide (LPS)-treated human umbilical vein endothelial cells (HUVECs), ANGPT1 decreased levels of clotting factors compared with...
16:50 , Oct 17, 2017 |  BC Innovations  |  Distillery Therapeutics

Ophthalmic disease

INDICATION: Glaucoma Mouse studies suggest activating Tie2 could help treat primary open-angle glaucoma (POAG). In a mouse model of POAG, intraocular injection of a Tie2-activating antibody decreased intraocular pressure compared with a control antibody. Next...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

Trebananib: Additional Phase III data

Additional data from the double-blind, international Phase III TRINOVA-1 trial in over 900 women with recurrent partially platinum-sensitive or platinum-resistant ovarian cancer, primary peritoneal cancer or fallopian tube cancer showed that once-weekly 15 mg/kg IV...
07:00 , Oct 27, 2014 |  BioCentury  |  Emerging Company Profile

Vasomune: Lassoing Tie2

Agonizing Tie2 could restore vascular integrity and limit tissue damage in kidney injury, but bringing together the four copies needed to activate the receptor is a job too big for small molecules or antibodies. Vasomune...
07:00 , Oct 13, 2014 |  BioCentury  |  Strategy

Streamlining Takeda's Profit Story

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...
08:00 , Feb 3, 2014 |  BioCentury  |  Product Development

Spies graduate

The initial results from I-SPY 2 are a fine rebuttal to industry skeptics who doubted the academic groups in charge had the ability to quickly run a robust clinical trial across multiple tumor types. In...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Retinopathy Angiopoietin 1 (ANG1; ANGPT1) Mouse studies suggest ANG1 could help treat retinopathy of prematurity (ROP) and proliferative diabetic retinopathy...
07:00 , Sep 9, 2013 |  BioCentury  |  Strategy

Setting Amgen's targets

Amgen Inc. 's proposed acquisition of Onyx Pharmaceuticals Inc. will more than double the bellwether's portfolio of marketed targeted cancer therapeutics, putting it in a tie with GlaxoSmithKline plc for second place behind Roche and...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Trebananib: Phase III data

Top-line data from the double-blind, international Phase III TRINOVA-1 trial in over 900 women with recurrent partially platinum-sensitive or platinum-resistant ovarian cancer, primary peritoneal cancer or fallopian tube cancer showed that once-weekly 15 mg/kg IV...
08:00 , Dec 13, 2012 |  BC Innovations  |  Tools & Techniques

Pulmonary edema on a chip

Researchers at the Harvard University have described the first disease model to emerge from the institute's organ-on-a-chip microfluidic device technology. 1,2 The model of pulmonary edema could be better than culture models at predicting whether...